K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 40.4 HKD -2.42% Market Closed
Market Cap: 11.1B HKD
Have any thoughts about
KeyMed Biosciences Inc?
Write Note

KeyMed Biosciences Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

KeyMed Biosciences Inc
Operating Income Peer Comparison

Comparables:
6160
603392
002252
300122
300896

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
K
KeyMed Biosciences Inc
HKEX:2162
Operating Income
-ÂĄ433.6m
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Operating Income
-ÂĄ8.8B
CAGR 3-Years
8%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Operating Income
ÂĄ1.4B
CAGR 3-Years
22%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Operating Income
ÂĄ2.3B
CAGR 3-Years
31%
CAGR 5-Years
46%
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Operating Income
ÂĄ7B
CAGR 3-Years
-7%
CAGR 5-Years
25%
CAGR 10-Years
50%
Imeik Technology Development Co Ltd
SZSE:300896
Operating Income
ÂĄ2.1B
CAGR 3-Years
64%
CAGR 5-Years
71%
CAGR 10-Years
N/A

See Also

What is KeyMed Biosciences Inc's Operating Income?
Operating Income
-433.6m CNY

Based on the financial report for Dec 31, 2023, KeyMed Biosciences Inc's Operating Income amounts to -433.6m CNY.

What is KeyMed Biosciences Inc's Operating Income growth rate?
Operating Income CAGR 3Y
20%

Over the last year, the Operating Income growth was 9%. The average annual Operating Income growth rates for KeyMed Biosciences Inc have been 20% over the past three years .

Back to Top